Lawrence Liu
Overview
Explore the profile of Lawrence Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monsoor T, Kanai S, Daida A, Kuroda N, Sinha P, Oana S, et al.
medRxiv
. 2025 Feb;
PMID: 39974054
Epilepsy affects 1% of the population, with up to one-third of patients being medication-resistant. Surgery is the only curative treatment, yet over one-third of surgical patients fail to achieve seizure...
2.
Liu L, Grandhi N, Wang M, Proskuriakova E, Thomas T, Schoen M, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2458585.
PMID: 39918819
Importance: Obesity is a risk factor associated with multiple myeloma (MM) and its precursor, monoclonal gammopathy of unknown significance (MGUS). However, it is unclear how cumulative exposure to obesity affects...
3.
Grandhi N, Liu L, Wang M, Thomas T, Schoen M, Sanfilippo K, et al.
JNCI Cancer Spectr
. 2024 Nov;
8(6).
PMID: 39514091
Background: In patients with diabetes and monoclonal gammopathy of uncertain significance (MGUS), the impact of glucagon-like peptide-1 (GLP-1) receptor agonists on the natural history of MGUS is unknown. We aimed...
4.
Woo J, Nguyen K, Liu L, Krishnan A, Siddiqi T, Borogovac A
Semin Hematol
. 2024 Sep;
61(5):273-283.
PMID: 39327109
Chimeric antigen receptor T-cell (CAR-T) therapy has heralded a new era in the treatment of various hematological malignancies, increasingly being utilized in earlier lines of therapy. Moreover, cellular therapies are...
5.
Zhang Y, Daida A, Liu L, Kuroda N, Ding Y, Oana S, et al.
medRxiv
. 2024 Jul;
PMID: 39040207
Objective: Interictal high-frequency oscillations (HFOs) are a promising neurophysiological biomarker of the epileptogenic zone (EZ). However, objective criteria for distinguishing pathological from physiological HFOs remain elusive, hindering clinical application. We...
6.
PyHFO: lightweight deep learning-powered end-to-end high-frequency oscillations analysis application
Zhang Y, Liu L, Ding Y, Chen X, Monsoor T, Daida A, et al.
J Neural Eng
. 2024 May;
21(3).
PMID: 38722308
. This study aims to develop and validate an end-to-end software platform, PyHFO, that streamlines the application of deep learning (DL) methodologies in detecting neurophysiological biomarkers for epileptogenic zones from...
7.
Northway S, Vallejo B, Liu L, Hansen E, Tang S, Mah D, et al.
J Appl Clin Med Phys
. 2023 Dec;
25(4):e14247.
PMID: 38131514
Background: Beam modifying accessories for proton therapy often need to be placed in close proximity of the patient for optimal dosimetry. However, proton treatment units are larger in size and...
8.
Wang M, Yu Y, Liu L, Schoen M, Kumar A, Vargo K, et al.
JCO Clin Cancer Inform
. 2023 Dec;
7:e2300081.
PMID: 38048516
Purpose: To develop and validate natural language processing (NLP)-assisted machine learning (ML)-based classification models to confirm diagnoses of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) from electronic...
9.
Peres L, Oswald L, Dillard C, De Avila G, Nishihori T, Blue B, et al.
Blood Adv
. 2023 Oct;
8(1):251-259.
PMID: 37855718
Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain US Food and Drug Administration approval for patients with relapsed/refractory multiple myeloma (RRMM). The clinical outcomes of...
10.
Liu L, Krishnan A
Haematologica
. 2023 Oct;
109(3):718-724.
PMID: 37855056
Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple...